IC
VIRX

Ikarian Capital’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Ikarian Capital’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-155,599
Closed -$1.44M – 305
2021
Q1 		$1.44M Buy
155,599
+98,456
+172% +$1.03M 0.05% 222
2020
Q4 		$398K Buy
+57,143
New +$298K 0.02% 199
2020
Q3 		– Sell
-3,184
Closed -$29K – 215
2020
Q2 		$29K Hold
3,184
– – ﹤0.01% 163
2020
Q1 		$46K Hold
3,184
– – ﹤0.01% 151
2019
Q4 		$38K Buy
+3,184
New +$53.3K 0.01% 111

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Ikarian Capital's VIRX Position: Q2 2021 in Review

Ikarian Capital sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2021, closing a stake of 155,599 shares — an estimated $1.44M sold.

Ikarian Capital first reported a position in VIRX in Q4 2019 and held it in 5 quarters. The position peaked at $1.44M in Q1 2021. 63 funds tracked by Wall St. Rank hold VIRX as of Q2 2021.

  • Ikarian Capital reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Ikarian Capital sold 155,599 Viracta Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $1.44M.
  • Ikarian Capital first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2019 and held it in 5 quarters.
  • Ikarian Capital's Viracta Therapeutics, Inc. Common Stock position peaked at $1.44M in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Ikarian Capital's 13F filing for Q2 2021, filed 16 Aug 2021.